Disclosures for "Safety and Tolerability of Daily Temozolomide After Dose-limiting Toxicities to Standard Therapy in Glioma Patients"
-
Dr. Godoy-Santin has nothing to disclose.
-
Ms. Granovskaya has nothing to disclose.
-
The institution of Dr. Calabrese has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Servier Pharmaceuticals. Dr. Calabrese has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Law Firms. The institution of Dr. Calabrese has received research support from ARRS. Dr. Calabrese has received publishing royalties from a publication relating to health care.
-
Mr. Wong has nothing to disclose.
-
Ms. bilodeau has nothing to disclose.
-
Dr. Lim Fat has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier. Dr. Lim Fat has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. The institution of Dr. Lim Fat has received research support from Brain Cancer Canada.
-
The institution of Dr. Perry has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Enveric Biosciences . The institution of Dr. Perry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier. The institution of Dr. Perry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. Dr. Perry has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Canadian Brain Tumour Consortium. Dr. Perry has stock in Synaptive Medical.